Cannon Developments

Sarah Cannon Research Institute (SCRI) is a leading global oncology research organization that specializes in community-based clinical trials and drug development. Founded in 1993, the institute has conducted more than 850 first-in-human clinical trials and has been a pivotal contributor to the research leading to the majority of new cancer therapies approved by the FDA over the last decade. SCRI operates as a joint venture between McKesson Corporation and HCA Healthcare, leveraging a vast network of over 250 research sites across the United States and United Kingdom. The organization provides comprehensive clinical development services, including trial management, regulatory support, and strategic consulting for pharmaceutical and biotechnology partners. By integrating research directly into community cancer centers, SCRI ensures that patients have access to cutting-edge therapies close to home.